

Insights into Life & Health reinsurance

Spotlight on longevity

Claude Chèvre, Member of the Executive Board 24th International Investors' Day 2021 Hannover, 14 October 2021



Agenda

- 1 Introduction
- 2 Spotlight on longevity
- 3 Life & Health earnings power
- 4 Key takeaways



Good performance in 2020 In each of the earnings growth drivers



Financial Solutions



Asia




Longevity




Normalised EBIT in m. EUR



Normalised EBIT in m. EUR.



Normalised EBIT in m. EUR






E: Expected normalised A: Actual





25 years of innovation

Continuous growth and expansion in the longevity market



Regular premium annuity treaty Currently the preferred option of our clients

Involved parties



Regular payments




Transaction



Floating leg
Fixed leg



Mechanics



Fixed leg Expected annuity payments including margin

Floating leg

Actual annuity payments

Data collection and monitoring Foundation of excellent performance

Figures in m. EUR (as @ 2020)

Treaty	PV claims @ quote	Claims paid	Realised margin	Future margin	Admin. expenses	Total margin	A/E @quote	Effect of ±1% qx
E								
E	1,492	44%	43	51	-6	89	96%	4.2
E	600	26%	6	61	-3	65	104%	2.2
E								
E								
Total	31,769	40%	524	1,191	-259	1,456	100%	88.2

A/E: Actual to Expected PV: Present value

Mortality improvements


Key ingredients of pricing and risk management




Today's 30-year-old males compared to 2021 older counterparts




Today's **60-year-old** males compared to 2021 older counterparts






somewhat diggerent

L&H earnings power



Longevity earnings

Reliable and positive contribution to the L&H business group



Continuous growth of expected EBIT Negatively impacted by COVID





Key takeaways



Longevity: past

- Outstanding reinsurance expertise
- Granular mortality experience
- Recurring innovative solutions
- Consistently strong performance
- Best in class reinsurer¹⁾


Longevity: future

- No surprise through close monitoring
- Strong resilience to mortality deviations
- Continued product innovation
- Further geographic expansion
- Extensive data collection

L&H business group

- Increasing underlying profitability
- VNB volatility due to Financial Solutions (FS) and Longevity
- EBIT volatility due to
 - · COVID (-)
 - Recaptures of FS deals (+)
 - At equity measurement of companies (-/+)

1) NMG Global L&H Reinsurance Study 2020



Disclaimer

This presentation does not address the investment objectives or financial situation of any particular person or legal entity. Investors should seek independent professional advice and perform their own analysis regarding the appropriateness of investing in any of our securities.

While Hannover Re has endeavoured to include in this presentation information it believes to be reliable, complete and up-to-date, the company does not make any representation or warranty, express or implied, as to the accuracy, completeness or updated status of such information.

Some of the statements in this presentation may be forward-looking statements or statements of future expectations based on currently available information. Such statements naturally are subject to risks and uncertainties. Factors such as the development of general economic conditions, future market conditions, unusual catastrophic loss events, changes in the capital markets and other circumstances may cause the actual events or results to be materially different from those anticipated by such statements.

This presentation serves information purposes only and does not costitute or form part of an offer or solicitation to acquire, subscribe to or dispose of, any of the securities of Hannover Re.

© Hannover Rück SE. All rights reserved. Hannover Re is the registered service mark of Hannover Rück SE.

